*Stock prices used were the after-market prices of June 10, 2025. The video was published on June 10, 2025. In today's video, I discuss recent updates impacting Nvidia (NVDA 0.86%) and other semiconductor companies. To learn more, check out the short video, consider subscribing, and click the special offer link below. ...

Group 1 - Funko's net sales decreased by 11.6% to $190.7 million in the first quarter [1] - Despite the decline in sales, Funko's gross margin improved to 40.3% [1] Group 2 - The report suggests a resilient collector economy that continues to thrive [1]

10 June 2025 | 4:02PM EDT Cameco Corp. (CCJ): A new(er) revenue driver as Westinghouse poised to benefit from new reactor builds; raise estimates, PT; reiterate Buy Late last week, the Czech Republic and South Korea reached an agreement on a 2-reactor, ~$19bn project after a court overturned a legal challenge that had blocked the deal from going through (link). As Westinghouse and Korea Electric Power Corporation (KEPCO) and Korea Hydro & Nuclear Power Co. (KHNP) have a mutually beneficial framework agreeme ...

10 June 2025 | 11:03AM HKT China Semis: Longsys (301308.SZ): Memory module supplier expanding to enterprise market; Controller IC to ramp up in 2025E We talked to Longsys (301308.SZ, Not Covered) management recently. Longsys is memory module supplier and provides embedded memory, SSD, DRAM modules for consumer, automotive and enterprise clients. Overall, management is positive on company's expansion to enterprise market, driven by rising demand on storage solution with high bandwidth and low latency, with r ...

Group 1: Investment Themes - Zacks Thematic Screens offers insights into 30 dynamic investment themes, including technology, renewable energy, and healthcare innovations [1][10] - The China Technology theme focuses on China-based technology companies listed on the U.S. stock market, covering sectors like Internet services, e-commerce, and online gaming [5][3] Group 2: China Technology Sector - The China Technology sector is characterized by companies that are leaders in their fields, aiming to reduce reliance on Western technology amid Sino-U.S. trade tensions [3][4] - Recent U.S. restrictions on high-tech exports have prompted China to accelerate self-sufficiency efforts in critical industries, enhancing its position in technology [4] Group 3: NetEase Performance - NetEase (NTES) is highlighted as a top-ranked stock within the China Technology screen, benefiting from strong quarterly results and a favorable EPS outlook [2][6] - The company reported a 7% year-over-year revenue growth in its latest quarter, driven by popular games like Marvel Rivals [8][7]

Investment Rating - The report indicates an "Overweight" (OW) fundamental stock rating for several companies, suggesting a positive outlook for these stocks [2][24]. Core Insights - The alpha model MOST has outperformed for the fourth consecutive month, returning +12.4% over the past 12 months, with a significant portion of gains occurring in the current calendar year [2][19]. - The ASX200 index is trading at a forward multiple of 18.7x, which is 1.5x P/E points above the lows observed on April 7, reflecting a 16.4% increase since that date [11][13]. - Growth factors have been the best performing, with a composite growth factor return spread of +5.7% in May, while quality stocks with low leverage and high profitability have also shown strong gains [3][4]. Summary by Sections Stock Ideas - Top-ranked stocks with an OW rating and upside to price targets include ABB, BHP, EDV, IPH, MMS, ORI, PME, QAN, QBE, RDX, and SIG [2][24]. - High-quality companies preferred by the MOST model include ABB, APE, AX1, BHP, COL, DTL, EDV, FMG, IPH, PME, PMV, QBE, and RDX [4][5]. Market Observations - In May, high beta and volatile stocks outperformed, with the broader equity markets advancing from April lows [3]. - The ASX200 has adjusted higher, now trading at 18.7x 12-month forward P/E, indicating a shift in market sentiment towards higher valuations [8][11]. Performance Metrics - The MOST model has shown strong cumulative growth, with high-scoring stocks returning +5.9% in May, while low-scoring stocks returned +5.3% [19][22]. - The report highlights that multiple expansion has been a key driver of index returns, despite a moderation in earnings signals [11][16]. Screens and Stock Ratings - The report categorizes stocks into various buckets based on market capitalization and investment style, providing tailored stock ideas for different investment disciplines [4][10]. - Bottom-ranked stocks with an Underweight (UW) rating include WBC, ORG, and SFR, indicating a negative outlook for these companies [27][28].

Core Insights - ACM Research, Inc. has released its 2024 Environmental, Social, and Governance (ESG) report, now available in English, highlighting its commitment to sustainability in semiconductor manufacturing [1][2] Company Initiatives - The company emphasizes its dedication to improved ESG performance through innovations like the Tahoe hybrid cleaning system, which significantly reduces sulfuric acid usage, supporting a circular economy [2] - ACM completed its inaugural CDP Climate submission in 2024, enhancing climate risk disclosure and environmental transparency [3] ESG Metrics and Goals - ACM has established a carbon reduction baseline for future greenhouse gas emissions targets [7] - The company aims for a 75% pure water purification rate by 2030 [7] - In 2024, ACM recycled 2,800 kg of plastic crates and 1,200 kg of wooden crates as part of its circular economy initiatives [7] - An ESG risk screening system for suppliers is under development, with a planned launch in 2025 [7] Certifications and Achievements - ACM has maintained ISO 14001 and ISO 9001 certifications across key facilities [7] - The Ultra C Tahoe hybrid cleaning tool offers enhanced cleaning performance with up to 75% reduction in chemical consumption, leading to estimated cost savings of up to $500,000 per year from sulfuric acid alone [7] - The Frame Wafer cleaning tool achieves nearly 100% solvent recovery and filtration efficiency, significantly reducing chemical consumption during production [7]

Core Insights - ACM Research, Inc. has released its 2024 Environmental, Social, and Governance (ESG) report, highlighting its commitment to sustainability in semiconductor manufacturing [1][2] Group 1: ESG Report Highlights - The English version of the 2024 ESG report is now available on ACM's website, following the original Chinese version published in February 2025 [1] - ACM has established a carbon reduction baseline for future greenhouse gas (GHG) emissions targets [7] - The company aims to achieve a 75% pure water purification rate by 2030 [7] - In 2024, ACM recycled 2,800 kg of plastic crates and 1,200 kg of wooden crates as part of its circular economy initiatives [7] - An ESG risk screening system for suppliers is under development, with a planned launch in 2025 [7] Group 2: Innovations and Cost Savings - ACM's Ultra C Tahoe hybrid cleaning tool reduces chemical consumption by up to 75%, resulting in estimated cost savings of up to $500,000 per year from sulfuric acid alone [7] - The Frame Wafer cleaning tool achieves nearly 100% solvent recovery and filtration efficiency, significantly reducing chemical consumption during production [7] Group 3: Certifications and Climate Initiatives - ACM has maintained ISO 14001 and ISO 9001 certifications across key facilities [7] - The company completed its inaugural CDP Climate submission in 2024, enhancing climate risk disclosure and environmental transparency [3]

Summary of Embecta (EMBC) FY Conference Call - June 10, 2025 Company Overview - **Company**: Embecta (formerly part of Becton Dickinson's diabetes care business) - **Revenue**: Approximately $1.1 billion - **Product Categories**: - Pen needles - Conventional syringes - Safety products for injections - **Geographic Revenue Distribution**: - 50% from the US - ~30% from Europe, Middle East, and Africa - ~20% from Asia Pacific (including China) - ~5% from Latin America - **Business Model**: Focused on single-use disposable products for diabetes management, with a stable and recurring revenue base [4][5][6] Financial Performance and Projections - **Historical Performance**: - Revenue growth from 2022 to 2024 was around 1.3% CAGR, exceeding initial expectations of flat growth [11] - Adjusted EBITDA margins improved to 31.4%, surpassing the target of 30% despite facing inflationary pressures [13] - **Future Projections (2025-2028)**: - Expected constant currency revenue CAGR remains flattish, with a target of low single-digit growth [15] - Projected cumulative free cash flow of at least $600 million from 2026 to 2028, with plans to reduce debt by $450 million to $500 million during this period [15][49] - **Challenges**: - Decline in conventional syringe business in the US, projected to drop from $90 million in 2019 to around $35 million by 2025 [18] - Impact of pharmacy closures affecting inventory purchases and revenue [38] Growth Opportunities - **GLP-1 Market**: - Identified as the single biggest growth opportunity, with expectations for multi-dose pen injectors to replace single-use auto injectors [30][31] - Anticipated market opportunity of at least $100 million by 2033, with potential revenue contributions starting as early as 2026 [32][33] - **New Product Revenue Streams**: - Entering distribution agreements for products like blood glucose monitors and insulin pumps to diversify offerings [35] Operational Insights - **Manufacturing and Supply Chain**: - Transitioning to a new ERP system and establishing independent distribution networks post-spin from Becton Dickinson [8][9] - Current gross margins around 63%, with expectations for slight declines due to tariffs and increased R&D expenses [40][41] - **Debt Management**: - Current net leverage at 3.7 times, with a goal to reduce it to around 2 times by 2028 [48][49] Market Dynamics - **Geographic Growth**: - Emerging markets expected to grow at mid-single digits, while US business projected to see low single-digit declines [26][27] - **Impact of Formulary Changes**: - Generally viewed as beneficial if they make insulin more affordable for patients [25] Conclusion - **Investor Sentiment**: - Positive reception post-Analyst Day, with a focus on cautious and achievable financial projections [54][55] - **Future Outlook**: - The company aims to leverage its free cash flow capabilities to enhance its product portfolio and maintain stable growth despite market challenges [10][55]

Core Insights - The individual has retired after over 43 years in investment research, now operating independently to provide actionable investment insights [1] - The focus is on rules and factor-based equity investing strategies, emphasizing the importance of human intelligence in generating investment stories rather than solely relying on quantitative data [1] - The approach combines factor analysis with classic fundamental analysis to understand the true story of a company and its stock, highlighting the limitations of historical data in predicting future performance [1] Experience and Background - The individual has extensive experience covering a wide range of stocks, including large cap, small cap, micro cap, value, growth, and income [1] - Previous roles include managing a high-yield fixed-income fund and conducting research on quantitative asset allocation strategies, which are foundational to modern Robo Advising [1] - The individual has authored two books on stock selection and analysis and has a passion for investor education, having conducted numerous seminars [1]